AstraZeneca stock: Jefferies keeps GBp 17,500 target for AstraZeneca stock

Published on 10/23/2026 at 15:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 15.38 billion, up 6.40 percent year over year. AstraZeneca stock costs EUR 152.88 during trading on October 23, 2026.

Analyst view and reporting dates

Jefferies kept its Buy rating and GBp 17,500.00 target on October 20, 2026.
AstraZeneca reported USD 15.38 billion in second-quarter 2026 revenue, up 6.40 percent year over year.
AstraZeneca stock traded at EUR 152.88 at Lang & Schwarz on October 23, 2026 at 3:37 p.m. CEST.
The company listed an ESMO management event for October 26, 2026 and results for October 30, 2026.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

Jefferies maintained its Buy rating and a GBp 17,500.00 price target for AstraZeneca on October 20, 2026, according to MarketScreener. The target stood 34.82 percent above the GBp 12,980.00 London quote dated October 22, 2026. AstraZeneca was trading at EUR 152.88 at Lang & Schwarz on October 23, 2026 at 3:37 p.m. CEST.

Analyst target stays elevated

Jefferies' unchanged view places the target well above the London share price, but the recommendation itself was not upgraded. The October 20 note kept the Buy rating and the GBp 17,500.00 target, making the distance between the target and the dated London quote the clearest numerical feature of the latest analyst view.

Second-quarter figures show growth

AstraZeneca reported USD 15.38 billion in revenue for the second quarter of 2026, up 6.40 percent from the same quarter a year earlier, according to TickerScout. Net income attributable to shareholders reached USD 2.51 billion, an increase of 2.30 percent, while operating profit fell 9.80 percent to USD 3.16 billion. The contrasting figures leave revenue growth intact while reported operating profit remains the weaker part of the quarter.

Upcoming dates matter

AstraZeneca's investor-relations calendar lists an ESMO management event for October 26, 2026 and the company's nine-month and third-quarter 2026 results for October 30, 2026, according to AstraZeneca. The results date is the next scheduled reporting milestone, while the ESMO event comes four days earlier.

Price remains the market frame

The euro quotation gives German investors a direct intraday reference for the stock, while the dated London quote provides the home-market context. AstraZeneca operates in healthcare and drug manufacturing, with its primary listing on the London Stock Exchange. Its second-quarter revenue and net-income comparisons provide the latest reported operating benchmarks before the October 30 results.

Stock and investor calendar

The analyst target, quarterly growth and upcoming events give investors three separate reference points for the stock. Jefferies' GBp 17,500.00 target is an analyst view rather than company guidance, while the USD 15.38 billion quarterly revenue figure is an historical reported result. The October 26 and October 30 dates provide the next scheduled opportunities for company-specific information.

The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.